EpiCast Report: Osteoporosis - Epidemiology Forecast to 2022

EpiCast Report: Osteoporosis - Epidemiology Forecast to 2022

The lifetime risk of osteoporotic fracture is 50% in women and 10%-30% in men (Randell et al., 1995). The morbidity and mortality associated with osteoporotic fractures make osteoporosis a global health burden, second only to cardiovascular disease (Woolf, 2000). Over the next decade, there will be a 26.8% increase in the prevalent cases of osteoporosis in the nine markets. In 2012, there were 164 million prevalent cases of osteoporosis in the nine markets, with more than 100 million cases in India and China. GlobalData epidemiologists forecast that there will be 208 million prevalent cases in the nine markets by 2022, with 142 million cases in India and China. GlobalData epidemiologists forecast that the number of prevalent cases of osteoporosis will increase dramatically in all nine markets during the forecast period. Because they chose a conservative approach and applied the same prevalence rate during the forecast period, the change in the number of prevalent cases can be attributed to the projected changing demographics in the population over the age of 40 in each of the nine markets. In the absence of comparable historical data for osteoporosis, GlobalData epidemiologists assumed that the most recently published prevalence data would be reflective of the disease prevalence over the next decade. However, such an approach is also likely to underestimate the number of prevalent cases of osteoporosis in the emerging markets.

To purchase and know more about this report please visits: EpiCast Report: Osteoporosis - Epidemiology Forecast to 2022

 

Scope

• The Osteoporosis EpiCast Report provide an overview of the risk factors and global trends of osteoporosis in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to emerging markets—India and China. 
• It includes a 10-year epidemiological forecast of osteoporosis prevalence segmented by gender and age (40-49, 50-59, 60-69, 70-79, and =80 years).

 

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global osteoporosis market.
• Quantify patient populations in the global osteoporosis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age group and gender that present the best opportunities for osteoporosis therapeutics in each of the markets covered.
• Quantify patient populations that had vertebral fractures confirmed by lateral X-rays and osteoporosis confirmed by dual-energy X-ray absorptiometry (DXA), based on the standardized World Health Organization (WHO) disease definition.